Source: European Medicines Agency (EU) Revision Year: 2012 Publisher: Eli Lilly Nederland B.V., Grootslag 1-5, 3991 RA, Houten, The Netherlands
Xigris 20 mg powder for solution for infusion.
Pharmaceutical Form |
---|
Powder for solution for infusion. Xigris is supplied as a lyophilised, white to off-white powder. |
Each vial contains 20 mg of Drotrecogin alfa (activated).
After reconstitution with 10 ml of Water for Injection each ml contains 2 mg of Drotrecogin alfa (activated).
Drotrecogin alfa (activated) is a recombinant version of the endogenous activated Protein C and is produced by genetic engineering from an established human cell line.
Excipient: Each vial contains approximately 68 mg sodium.
For a full list of excipients, see 6.1.
Active Ingredient | Description | |
---|---|---|
Drotrecogin alfa |
Drotrecogin alfa is a recombinant version of the natural plasma-derived activated Protein C, from which it differs only by unique oligosaccharides in the carbohydrate portion of the molecule. Activated Protein C is a crucial coagulation regulator. Furthermore, Activated Protein C is an important modulator of the systemic response to infection and has antithrombotic and profibrinolytic properties. Drotrecogin alfa has similar properties to those of endogenous human Activated Protein C. |
List of Excipients |
---|
Sucrose |
Powder in Type I glass vial. Pack of 1 vial.
Eli Lilly Nederland B.V., Grootslag 1-5, 3991 RA, Houten, The Netherlands
EU/1/02/225/002
Date of first authorisation: 22 August 2002
Drug | Countries | |
---|---|---|
XIGRIS | South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.